Free Trial
NYSE:ANRO

Alto Neuroscience (ANRO) Stock Price, News & Analysis

Alto Neuroscience logo
$2.31 -0.11 (-4.36%)
Closing price 03/28/2025 03:59 PM Eastern
Extended Trading
$2.34 +0.03 (+1.30%)
As of 03/28/2025 05:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Alto Neuroscience Stock (NYSE:ANRO)

Key Stats

Today's Range
$2.27
$2.40
50-Day Range
$2.31
$4.84
52-Week Range
$2.24
$17.55
Volume
157,461 shs
Average Volume
361,022 shs
Market Capitalization
$62.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.75
Consensus Rating
Moderate Buy

Company Overview

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Remove Ads

Alto Neuroscience Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
35th Percentile Overall Score

ANRO MarketRank™: 

Alto Neuroscience scored higher than 35% of companies evaluated by MarketBeat, and ranked 783rd out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alto Neuroscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Alto Neuroscience has only been the subject of 1 research reports in the past 90 days.

  • Read more about Alto Neuroscience's stock forecast and price target.
  • Earnings Growth

    Earnings for Alto Neuroscience are expected to grow in the coming year, from ($2.54) to ($2.39) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Alto Neuroscience is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Alto Neuroscience is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Alto Neuroscience's valuation and earnings.
  • Percentage of Shares Shorted

    16.26% of the float of Alto Neuroscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Alto Neuroscience has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Alto Neuroscience has recently increased by 1.08%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Alto Neuroscience does not currently pay a dividend.

  • Dividend Growth

    Alto Neuroscience does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.26% of the float of Alto Neuroscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Alto Neuroscience has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Alto Neuroscience has recently increased by 1.08%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Alto Neuroscience has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Alto Neuroscience this week, compared to 2 articles on an average week.
  • Search Interest

    10 people have searched for ANRO on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Alto Neuroscience to their MarketBeat watchlist in the last 30 days.
Receive ANRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alto Neuroscience and its competitors with MarketBeat's FREE daily newsletter.

ANRO Stock News Headlines

Analysts Set Expectations for ANRO Q1 Earnings
Why Buffett and 100 members of Congress are Piling into this One Investment
While everyone's distracted by the recent stock market rally and Trump's tariffs... There's a much bigger story that's flying under the radar for now: Why are Warren Buffett, Ken Griffin, Roman Abramovich, the Koch Brothers, Carlos Slim and at least 100 members of Congress all going against "conventional wisdom?" And why are they all piling into ONE overlooked corner of the stock market? It's not crypto... gold... or options strategies.
Brokerages Set Alto Neuroscience, Inc. (NYSE:ANRO) PT at $16.75
See More Headlines

ANRO Stock Analysis - Frequently Asked Questions

Alto Neuroscience's stock was trading at $4.23 at the beginning of 2025. Since then, ANRO shares have decreased by 45.5% and is now trading at $2.3050.
View the best growth stocks for 2025 here
.

Alto Neuroscience, Inc. (NYSE:ANRO) released its quarterly earnings results on Thursday, March, 20th. The company reported ($0.56) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.09.

Alto Neuroscience (ANRO) raised $129 million in an initial public offering (IPO) on Friday, February 2nd 2024. The company issued 8,040,000 shares at $16.00 per share.

Top institutional shareholders of Alto Neuroscience include Point72 Asset Management L.P. (6.27%), Franklin Resources Inc. (4.31%), Vestal Point Capital LP (3.39%) and Price T Rowe Associates Inc. MD (3.13%). Insiders that own company stock include Wave Global Lp Alpha, Adam Savitz and Nicholas Conrad Smith.
View institutional ownership trends
.

Shares of ANRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alto Neuroscience investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

Last Earnings
3/20/2025
Today
3/30/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:ANRO
Previous Symbol
NYSE:ANRO
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.75
High Stock Price Target
$43.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+626.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-36,310,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$62.40 million
Optionable
N/A
Beta
N/A
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NYSE:ANRO) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners